A year-long (at least) delay of taspoglutide, the Phase III diabetes candidate from Ipsen SA and Roche AG, provides a welcome lift for Amylin Pharmaceuticals Inc.'s would-be competitor Bydureon, though the hypersensitivity reactions holding up the former once-weekly glucagon-like peptide-1 analogue could cast some doubt on the class to which Bydureon also belongs. (BioWorld Today) Read More
